This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?
by Zacks Equity Research
Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.
What Makes AC Immune (ACIU) a New Buy Stock
by Zacks Equity Research
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AC Immune Enters Oversold Territory
by Zacks Equity Research
AC Immune SA (ACIU) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Roche Halts Two Late-Stage Studies on Alzheimer's Candidate
by Zacks Equity Research
Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
Top Ranked Momentum Stocks to Buy for January 25th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 25th:
Top Ranked Momentum Stocks to Buy for January 23rd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:
Top Ranked Momentum Stocks to Buy for January 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 22nd:
Moving Average Crossover Alert: AC Immune
by Zacks Equity Research
AC Immune SA (ACIU) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher
by Zacks Equity Research
Stemline Therapeutics (STML) shares rose nearly 10% in the last trading session, amid huge volumes.
Biogen Inks Two Deals to Make Drugs for Neurological Diseases
by Zacks Equity Research
Biogen (BIIB) signs deals with C4 Therapeutics and Skyhawk Therapeutics to develop potential therapies for Alzheimer's disease (AD), Parkinson's disease and other neurological diseases.
Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug
by Zacks Equity Research
Eli Lilly (LLY) signs a deal with AC Immune to jointly develop Morphomer tau aggregation inhibitors, which have the potential to treat Alzheimer's disease (AD) and other neurodegenerative diseases.
AC Immune (ACIU) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in AC Immune SA (ACIU).
Top Ranked Momentum Stocks to Buy for November 21st
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 21st:
AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of 30.77% and 36.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
by Zacks Equity Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of 13.04% and 5.78%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Puma Biotech (PBYI) in Q2 Earnings?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) second-quarter 2018 earnings call, investor focus will be on the sales figures of its only marketed drug Nerlynx.
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
During Inovio's (INO) second-quarter 2018 earnings call, investor focus will remain on the company's progress with its lead candidate VGX-3100.
Moving Average Crossover Alert: AC Immune SA (ACIU)
by Zacks Equity Research
AC Immune SA (ACIU) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Fortress Biotech (FBIO) Looks Good: Stock Adds 5% in Session
by Zacks Equity Research
Fortress Biotech, Inc. (FBIO) shares rose over 5% in the last trading session.